Post herpetic neuralgia (PHN) is a chronic condition characterized by persistent pain following a herpes zoster (shingles) infection.
While various treatment options exist, emerging research suggests that cannabis strains, including indica and sativa, may offer potential therapeutic benefits in managing post herpetic neuralgia symptoms.
However, it is crucial to consult with a healthcare professional before considering cannabis as a treatment option.
Cannabis and its Potential in Post Herpetic Neuralgia Treatment
Cannabis contains cannabinoids, such as THC and CBD, which have been shown to possess analgesic properties.
These cannabinoids interact with receptors in the endocannabinoid system, potentially reducing pain signals and providing relief from post herpetic neuralgia pain.
Indica and sativa strains may help alleviate pain associated with PHN.
Cannabinoids in cannabis exhibit anti-inflammatory properties, which can be beneficial in reducing inflammation and alleviating the associated pain in post herpetic neuralgia.
By modulating the immune response, cannabis strains may help in managing the inflammatory component of PHN.
Sativa and Indica Strains
Sativa strains are often associated with uplifting and energizing effects. They can provide mental stimulation and promote a sense of focus.
For individuals with post herpetic neuralgia, sativa strains may offer relief without inducing excessive sedation, allowing them to engage in daily activities while managing pain.
Indica strains are known for their relaxing and sedating effects. They can induce a state of calmness and help individuals manage pain, promoting better sleep and overall well-being. Indica strains may be particularly beneficial during periods of heightened pain or when a more sedating effect is desired.
Research Evidence
One notable study conducted to investigate the potential benefits of cannabis in post herpetic neuralgia treatment is:”Cannabis-based medicines for chronic neuropathic pain in adults” (Mücke et al., 2018)
This systematic review examined the efficacy and safety of cannabis-based medicines in managing chronic neuropathic pain, including post herpetic neuralgia. The findings indicated that cannabis-based medicines, containing THC and/or CBD, were associated with a reduction in pain intensity and improved sleep quality.
Cautionary Measure
While cannabis strains, including indica and sativa, may offer potential benefits in managing post herpetic neuralgia symptoms, it is crucial to consult with a healthcare professional before use.
They can provide personalized guidance, assess potential drug interactions, and ensure compliance with legal regulations.
Conclusion
Cannabis strains show promise in managing post herpetic neuralgia by potentially reducing pain, inflammation, and improving sleep quality.
However, further research is needed to establish their efficacy, optimal dosages, and long-term effects specifically for post herpetic neuralgia treatment.
Individuals with post herpetic neuralgia should engage in open and informed discussions with healthcare professionals to determine the most appropriate treatment approach for their specific condition.
Combining medical expertise with the potential benefits of cannabis strains can support comprehensive strategies for managing PHN and improving overall quality of life.
References
Mücke, M., Phillips, T., & Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews, 3(3), CD012182.
Rice, A. S., & Cannabinoids and pain. British Journal of Pharmacology, 166(4), 1444-1464.
Blake, D. R., Robson, P., & Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology, 45(1), 50-52.
Abrams, D. I., & The therapeutic effects of cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report. European Journal of Internal Medicine, 49, 7-11.
Ware, M. A., Wang, T., & Cannabis for the management of pain: Assessment of safety study (COMPASS). Journal of Pain, 16(12), 1233-1242.
